p40-EBI3 Cytokine Complex Assembly for Immune Disease Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective methods for preventing or treating immune diseases related to cytokines such as IL-12, IL-23, IL-27, and IL-35, particularly in the form of heterodimeric complexes involving the p40 and EBI3 subunits, which are important regulators of inflammatory diseases and T cell-dependent immunity.
Innovation Solution
A complex is formed by linking the p40 subunit and the EBI3 subunit using a linker, encoded by specific amino acid and polynucleotide sequences, and optionally including an immunoglobulin moiety, which can be delivered via vectors to host cells for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heterodimeric cytokine complexes (IL-12, IL-23, IL-27, IL-35) are used to regulate immune responses, then T cell-dependent immunity is mediated and inflammatory diseases are regulated, but the lack of effective therapeutic methods prevents adequate treatment of immune diseases
Solution Approach 1:
The invention segments the cytokine complex into two separate subunits (p40 and EBI3) that can be independently produced and then assembled. This segmentation allows for easier manufacturing through separate expression systems while maintaining the functional integrity of the heterodimeric complex for effective immune disease treatment
Solution Approach 2:
The invention introduces a linker peptide as an intermediary component that facilitates the assembly of p40 and EBI3 subunits into the functional heterodimeric complex. This intermediary enables controlled formation of the cytokine complex with desired stoichiometry and stability, bridging the gap between simple subunit production and functional complex assembly
2Reliability
If p40 subunit is produced as homodimer or monomer, then it can act as antagonist of IL-12 function, but it lacks the full immunomodulatory activity of the heterodimeric complex
Solution Approach 1:
The linker peptide serves as a mediator that directs the assembly of p40 and EBI3 into the heterodimeric complex with proper stoichiometry. This intermediary control mechanism ensures formation of the biologically active heterodimer rather than inactive homodimers or monomers, achieving full immunomodulatory activity
Solution Approach 2:
The invention changes the assembly parameters by controlling the molar ratio of p40 to EBI3 subunits during co-expression or assembly conditions. By optimizing these parameters (subunit ratio, expression timing, cellular environment), the heterodimeric complex forms preferentially over homodimers, achieving the desired immunomodulatory activity
Data Source
AI summary
The present invention relates to a novel complex that is formed by linking p40 subunit and EBI3 subunit via a linker and has excellent anti-inflammatory effects and immunomodulatory effects.